VIVEbiotech, a San Sebastian, Spain-based lentiviral vector contract development and manufacturing organization (CDMO), received a growth equity investment from Ampersand Capital Partners.
The amount of the deal was not disclosed. As part of the transaction, industry veteran Dr. Stefan Beyer has been named Chairman of VIVEbiotech.
The company intends to use the funds to enable its lentiviral vector manufacturing in Spain and support the execution of a pipeline of customer projects for innovators developing in vivo and ex vivo cell and gene therapies.
Led by CEO Jon Alberdi, VIVEbiotech provides process development, manufacturing and analytical testing for biopharmaceutical companies engaged in gene therapy and cell therapy projects. VIVEbiotech provides process development, manufacturing and analytical testing for biopharmaceutical companies engaged in gene therapy and cell therapy projects. With a specific focus on lentiviral vector production, the company operates a state-of-the-art, 3,000 sq. m. (32,000 sq. ft.) GMP-compliant facility in San Sebastian, Gipuzkoa, Spain.
